GlassScriptPhysician profile
Iraj Mirshahi
NPI 1932135308
$1,761.02
in general payments reported to CMS, 2019-2025
32 companies · $22.34 in 2025
The $22.34 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $505 · 2020: $94.00 · 2021: $81.91 · 2022: $412 · 2023: $477 · 2024: $169 · 2025: $22.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $668.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $234.32 | 2019-2023 | Rybelsus, Ozempic |
| Abbvie INC. | $166.60 | 2022-2023 | |
| Abbott Laboratories | $166.33 | 2022-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $106.85 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $102.21 | 2019-2023 | Farxiga, Breztri |
| Amgen INC. | $100.37 | 2019-2023 | Repatha, Otezla |
| Lilly USA, LLC | $93.20 | 2019-2023 | Trulicity, Mounjaro |
| Pfizer INC. | $66.55 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $60.98 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $55.66 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.21 | 2022-2023 | |
| Dexcom, INC. | $50.05 | 2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $44.76 | 2022 | |
| Philips North America LLC | $42.20 | 2024 | (Ck6) Holter |
| Janssen Pharmaceuticals, INC | $39.01 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $37.26 | 2019-2023 | Yupelri |
| Avanir Pharmaceuticals, INC. | $35.39 | 2019 | |
| Glaxosmithkline, LLC. | $33.64 | 2019-2023 | Trelegy Ellipta |
| Ucb, INC. | $31.30 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $28.13 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.54 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $24.25 | 2022 | |
| Melinta Therapeutics, LLC | $21.79 | 2019 | |
| Astellas Pharma US INC | $19.11 | 2019 | |
| Dynavax Technologies Corporation | $18.55 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.99 | 2019 | |
| Scilex Pharmaceuticals INC. | $17.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.96 | 2023 | Jardiance |
| Edwards Lifesciences Corporation | $15.11 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Amarin Pharma, INC. | $14.00 | 2019 | |
| Shire North American Group INC | $13.03 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iraj Mirshahi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.